Seema Bhan
Consultant / Advisor at Exai Bio, Inc.
Profile
Seema Singh Bhan is a passionate leader who brings over two decades of experience in government affairs, public policy and advocacy.
Standing squarely at the intersection of transformative science and public policy, she is driven by her commitment to promote access for all to benefit from breakthroughs in science and technology.
Seema most recently served as Senior Vice President of Public Policy and External Affairs at Thrive Earlier Detection (now an Exact Sciences Company).
In the multi-cancer early detection space at Thrive she built the strategy that aligned and ignited policy partners–elected officials, patient advocates, and leaders across the public, private and academic sectors–around a bipartisan effort to ensure policies were in place for the adoption of such groundbreaking cancer diagnostics.
Prior to joining Thrive, Seema was Vice President, Head of Public Policy for Foundation Medicine, where she developed and executed company positions before Congress and other policymakers, including the landmark parallel review decision by the US Food and Drug Administration and the Centers for Medicare and Medicaid Services around next generation sequencing.
She was instrumental in ensuring broad health insurance reimbursement for Foundation Medicine’s flagship test, FoundationOne CDx.
Seema has also spent well over a decade in public service as senior counsel to Senator Arlen Specter and the Senate Judiciary Committee, where she was lead policy and strategic advisor for key issues including those related to tax, banking, healthcare and finance.
She provided policy analysis and strategic counsel to both Chairman Specter and Republican and Democrat senators on the Committee.
Seema lives outside of Philadelphia with her husband and two sons.
She loves spending time outdoors, exploring and supporting all Philly sports teams.
Seema Bhan active positions
Companies | Position | Start |
---|---|---|
Exai Bio, Inc.
Exai Bio, Inc. Packaged SoftwareTechnology Services Exai Bio, Inc. is an American next-generation liquid biopsy company founded by Hani Goodarzi, Babak Alipanahi, and Patrick Arensdorf. The company's mission is to enable early detection, accurate diagnosis, personalized and targeted treatment, and ultimately cure of cancer. Exai Bio's proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest and most accurate diagnosis of cancer. Patrick Arensdorf has been the CEO since incorporation. | Consultant / Advisor | 02/01/2023 |
Section 32 LLC
Section 32 LLC Investment ManagersFinance Section 32 LLC (Section 32) is a venture capital firm founded in 2017 by Bill Maris. The firm is headquartered in Silicon Valley, California. | Consultant / Advisor | - |
Former positions of Seema Bhan
Companies | Position | End |
---|---|---|
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Private Equity Investor | 31/01/2023 |
Foundation Medicine GmbH
Foundation Medicine GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Foundation Medicine GmbH is a German company that provides technical testing and analysis services. The company is based in Penzberg, Germany. | Private Equity Investor | 30/09/2019 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Foundation Medicine GmbH
Foundation Medicine GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Foundation Medicine GmbH is a German company that provides technical testing and analysis services. The company is based in Penzberg, Germany. | Commercial Services |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Health Technology |
Exai Bio, Inc.
Exai Bio, Inc. Packaged SoftwareTechnology Services Exai Bio, Inc. is an American next-generation liquid biopsy company founded by Hani Goodarzi, Babak Alipanahi, and Patrick Arensdorf. The company's mission is to enable early detection, accurate diagnosis, personalized and targeted treatment, and ultimately cure of cancer. Exai Bio's proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest and most accurate diagnosis of cancer. Patrick Arensdorf has been the CEO since incorporation. | Technology Services |
Section 32 LLC
Section 32 LLC Investment ManagersFinance Section 32 LLC (Section 32) is a venture capital firm founded in 2017 by Bill Maris. The firm is headquartered in Silicon Valley, California. | Finance |
- Stock Market
- Insiders
- Seema Bhan